IceCure Medical Discloses Going Concern Doubt, Reports $4.7M Cash Balance, and CFO Resignation
ICCM sits 30% above its 52-week low of $0.54 on elevated volume (2.0× avg).
Summary
IceCure Medical Ltd. has disclosed substantial doubt about its ability to continue as a going concern, with only $4.7 million in cash as of March 13, 2026, insufficient to fund operations for the next 12 months. The company also announced its CFO's resignation and reported a net loss of $15.057 million for 2025, despite recent capital raises and positive regulatory updates.
Key Events · Financing and Capital Events · ICCM
-
Going Concern Warning Issued
Management has concluded there is substantial doubt about the company's ability to continue as a going concern, with cash and equivalents of $4.7 million as of March 13, 2026, insufficient for the next 12 months.
-
Chief Financial Officer Resigned
Ronen Tsimerman, the Chief Financial Officer, resigned on February 9, 2026, and will continue to serve until a successor is appointed.
-
Annual Financial Results Reported
The company reported a net loss of $15.057 million for the year ended December 31, 2025, on revenues of $3.379 million, a 3% increase from 2024.
-
Recent Capital Raises Completed
A $10 million rights offering was completed in August 2025, and $6.6 million in shares were sold through an ATM facility as of March 13, 2026, to address liquidity needs.
Analysis · ICCM · Industrial Applications And Services
IceCure Medical Ltd. has issued a critical disclosure, stating that management has concluded there is substantial doubt about the company's ability to continue as a going concern. This is primarily due to a low cash balance of $4.7 million as of March 13, 2026, which is insufficient to fund planned operations for the next 12 months. The company also reported a net loss of $15.057 million for the year ended December 31, 2025, despite a 3% increase in revenues. Further compounding the challenges, the Chief Financial Officer, Ronen Tsimerman, resigned on February 9, 2026. While the company has recently completed a $10 million rights offering and sold $6.6 million in shares through an At-The-Market (ATM) facility, these capital raises are a response to its significant liquidity needs. Positive regulatory developments, such as FDA marketing authorization for its ProSense system and an updated ASBrS recommendation for cryoablation, offer long-term potential but do not alleviate the immediate financial distress.
At the time of this filing, ICCM was trading at $0.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $50.1M. The 52-week trading range was $0.54 to $1.53. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.